- Report
- August 2024
- 100 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- September 2023
- 105 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- March 2023
- 100 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- February 2023
- 100 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- April 2023
- 111 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- May 2024
- 132 Pages
Global
From €2690EUR$2,999USD£2,300GBP
€3587EUR$3,999USD£3,067GBP
- Report
- May 2024
- 135 Pages
Global
From €2690EUR$2,999USD£2,300GBP
€3587EUR$3,999USD£3,067GBP
- Report
- March 2024
- 200 Pages
Global
From €3723EUR$4,150USD£3,183GBP
- Report
- August 2022
- 119 Pages
Global
From €4037EUR$4,500USD£3,451GBP
- Report
- August 2025
- 191 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 193 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 192 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 199 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 181 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 184 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 198 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 186 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 180 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 193 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2025
- 184 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated.
Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss.
In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR.
The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR.
Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more